Strategic Innovation Board Member @ (January 2016 - Present)
SVP, Head of Program Strategy and Leadership @ (January 2026 - October 2026)
VP, Global Program Head, Oncology @ (August 2022 - January 2026)
Executive Director, Development Program Lead, Oncology Clinical Development @ (November 2020 - July 2022)
Clinical Development Lead, Oncology Clinical Development @ (January 2020 - November 2020)
Clinical Trial Lead, Oncology Clinical Development @ (August 2019 - January 2020)
Global Medical Lead, Lung Cancer @ (June 2018 - July 2019)
Global Medical Director, Lung Cancer @ (February 2017 - May 2018)
President, US Operations @ (May 2006 - February 2017)
Postdoctoral Fellow - Molecular Biology and Oncology @ (January 2005 - January 2006)
Postdoctoral Researcher - Molecular Biology and Oncology @ (January 2004 - January 2005)
Michael Mandola Education
University of Medicine and Dentistry of NJ (now Rowan University)
PhD (Molecular Biology)
2000-2004
Stockton University
BS (Biology)
1996-2000
Michael Mandola Skills
Biotechnology
Cancer
Clinical Development
Clinical Trials
Diabetes
Drug Development
Infectious Diseases
Life Sciences
Medical Affairs
Medical Education
Medical Writing
Medicine
Molecular Biology
Oncology
Pharmaceutical Industry
Publication Planning
Therapeutic Areas
Public Speaking
Teaching
Healthcare
Marketing
Customer Service
Project Management
Michael Mandola Summary
Michael Mandola, based in Princeton, NJ, US, is currently a Founder and Principal Consultant at Resurgent Therapeutics Advisory. Michael Mandola brings experience from previous roles at Stealth Biotech, The Max Foundation and Merck Healthcare. Michael Mandola holds a 2000 - 2004 PhD in Molecular Biology @ University of Medicine and Dentistry of NJ (now Rowan University). With a robust skill set that includes Biotechnology, Cancer, Clinical Development, Clinical Trials, Diabetes and more. Michael Mandola has 3 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Michael Mandola?
Find contact details for 700 million professionals.